| 1576 |
National Cancer Institute |
Html |
en |
Prostate Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for prostate cancer. |
| PDQ Screening | 0.238955 |
| prostate gland | 0.262783 |
| following PDQ summaries | 0.255959 |
| Cancer Information Service | 0.234967 |
| PDQ cancer information | 0.447798 |
| Prevention Editorial Board | 0.248763 |
| men | 0.210517 |
| National Cancer Institute | 0.335949 |
| clinical trials | 0.389256 |
| PDQ documents | 0.200757 |
| test result | 0.223183 |
| benign prostatic hyperplasia | 0.273839 |
| cancer information summary | 0.326548 |
| newly diagnosed prostate | 0.284247 |
| clinical trial | 0.213023 |
| new treatment | 0.208327 |
| breast cancer prevention | 0.217981 |
| early cancer detection | 0.236129 |
|
| Cancer screening trials | 0.28054 |
| test | 0.242059 |
| Cancer Care page | 0.221557 |
| PDQ database | 0.205174 |
| prostate cancer gene | 0.339499 |
| NCI’s PDQ | 0.209119 |
| prostate cancer screening | 0.411947 |
| PDQ summary | 0.286479 |
| cancer symptoms | 0.211597 |
| NCI PDQ cancer | 0.287762 |
| prostate cancer | 0.971006 |
| tests | 0.264624 |
| bigger prostate | 0.262229 |
| PSA test | 0.20487 |
| Prostate Cancer Prevention | 0.350483 |
| cancer information summaries | 0.242796 |
| comprehensive cancer information | 0.243032 |
| high PSA level | 0.200418 |
|
CLICK HERE |
| 1786 |
National Cancer Institute |
Html |
es |
Linfedema (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del linfedema. |
| siguientes áreas | 0.436931 |
| causa hinchazón | 0.778344 |
| pequeña cantidad | 0.464081 |
| pequeños cortes | 0.452311 |
| siguientes abordajes | 0.459419 |
| PDQ Linfedema | 0.618416 |
| sección información | 0.436578 |
| largo plazo | 0.580542 |
| protector solar | 0.453778 |
| sección manejo | 0.432902 |
| National Cancer Institute | 0.432858 |
| ropa flojos | 0.450402 |
| siguientes riesgos | 0.424859 |
|
| Instituto Nacional | 0.463187 |
| siguientes problemas | 0.490486 |
| linfedema atrapa | 0.967072 |
| Physician Data Query | 0.535003 |
| Estados Unidos | 0.442188 |
| estadio iii | 0.728645 |
| siguientes medidas | 0.469803 |
| linfa circula | 0.531655 |
| linfedema.ampliar anatomÃa | 0.480452 |
| siguientes pruebas | 0.475048 |
| uñas ayuda | 0.454713 |
| baja potencia | 0.433231 |
|
CLICK HERE |
| 1863 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia de células pilosas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia de células pilosas. |
| cell leukemia treated | 0.413444 |
| cell leukemia patients | 0.427269 |
| long-term follow-up | 0.427434 |
| Rituximab with pentostatin | 0.40359 |
| Peaud PY | 0.40245 |
| hairy cell leukaemia | 0.411122 |
| initially with pentostatin | 0.406363 |
| Foucar MK | 0.403895 |
| leukemia patients treated | 0.417121 |
| leukemia following treatment | 0.406508 |
| células pilosas | 0.473847 |
| treated with rituximab | 0.403745 |
| Instituto Nacional | 0.402568 |
| cell leukemia following | 0.408562 |
| Else M | 0.404329 |
| with pentostatin | 0.442439 |
| or refractory hairy | 0.403457 |
| VH4-34+ hairy cell | 0.404297 |
| Natl Cancer Inst | 0.402731 |
| Federico M | 0.402782 |
| Leuk Lymphoma | 0.424893 |
| long term | 0.40908 |
| patients treated with | 0.423309 |
| Burian C | 0.403658 |
| Matutes E | 0.403796 |
|
| leukemia treated with | 0.41301 |
| patients with hairy | 0.610395 |
| following treatment with | 0.408927 |
| Italian Cooperative Group | 0.40697 |
| hairy-cell leukemia with | 0.408245 |
| relapsed or refractory | 0.403586 |
| National Cancer Institute | 0.404377 |
| after treatment with | 0.408757 |
| untreated patients with | 0.407444 |
| with poor prognosis | 0.40323 |
| with 2-CdA | 0.403201 |
| cell leukemia with | 0.426877 |
| treatment with | 0.420376 |
| hairy cell leukemia | 0.998262 |
| Clin Oncol | 0.444146 |
| treated with pentostatin | 0.422653 |
| leukemia with pentostatin | 0.404444 |
| leukemia after treatment | 0.406381 |
| Long term results | 0.402405 |
| treated with | 0.429875 |
| treated initially with | 0.406289 |
| previously untreated patients | 0.40321 |
| PDQ Sofocos | 0.402915 |
| cell leukemia after | 0.412869 |
|
CLICK HERE |
| 1942 |
National Cancer Institute |
Html |
es |
Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocítica crónica o juvenil y la LMC atípica. |
| French-American-British Cooperative Leukaemia | 0.312371 |
| leucemia mieloide | 0.341853 |
| myelomonocytic leukaemia | 0.397359 |
| myelomonocytic leukemia with | 0.326213 |
| platelet-derived growth factor | 0.354049 |
| with juvenile chronic | 0.315892 |
| Arber DA | 0.312178 |
| health organization classification | 0.3281 |
| Leukemia Group | 0.315441 |
| genes platelet-derived growth | 0.312347 |
| with juvenile | 0.340061 |
| chronic myeloid leukemia | 0.336615 |
| myelomonocytic leukemia | 0.944712 |
| leucemia mielomonocÃtica | 0.387953 |
| chronic myelomonocytic leukemia | 0.819447 |
| differentiating myelomonocytic leukemia | 0.320578 |
| Beran M | 0.312167 |
| World Health Organization | 0.355665 |
| neoplasias mielodisplásicas | 0.314258 |
| stem cell transplantation | 0.313202 |
| chronic myelogenous leukemia | 0.364294 |
| Germing U | 0.362762 |
| myeloproliferative disorders | 0.313394 |
| cases with chronic | 0.311538 |
| Leuk Lymphoma | 0.332534 |
|
| myelomonocytic leukemia from | 0.33992 |
| chronic myelomonocytic leukaemia | 0.386185 |
| juvenile chronic myelogenous | 0.347073 |
| marrow transplantation | 0.341155 |
| Organización Mundial | 0.317633 |
| chronic myeloid | 0.357031 |
| Differentiating juvenile myelomonocytic | 0.319715 |
| myeloid neoplasms | 0.336696 |
| bone marrow transplantation | 0.325127 |
| Bennett JM | 0.319603 |
| cromosoma filadelfia | 0.337822 |
| recuento plaquetario | 0.325577 |
| juvenile myelomonocytic leukaemia | 0.339361 |
| juvenile myelomonocytic leukemia | 0.545157 |
| chronic myeloid leukaemias | 0.320258 |
| Clin Oncol | 0.32115 |
| Orazi A | 0.343564 |
| Cooperative Leukaemia Group | 0.311788 |
| atypical chronic | 0.319445 |
| caracterÃsticas clÃnicas | 0.316309 |
| trastornos mieloides | 0.311632 |
| leucemia mieloide aguda | 0.316238 |
| with chronic myelomonocytic | 0.340508 |
| Emanuel PD | 0.350668 |
|
CLICK HERE |
| 1946 |
National Cancer Institute |
Html |
es |
Tratamiento del neuroblastoma (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento del neuroblastoma. |
| glándula tiroides | 0.633074 |
| posibles efectos tardÃos | 0.641796 |
| siguientes procedimientos | 0.632822 |
| células madre | 0.931788 |
| gen alk | 0.612181 |
| siguientes especialistas | 0.624871 |
| yodo 131-mibg | 0.744725 |
| vÃa oral | 0.649411 |
| rayos x | 0.630232 |
| enlace drugs approved | 0.631928 |
| estadios 2A | 0.624814 |
| niño ayuda | 0.632627 |
| ondas sonoras | 0.629873 |
| riesgo intermedio | 0.674697 |
| efectos tardÃos | 0.896983 |
| cáncer.ampliar aspiración | 0.633221 |
|
| National Cancer Institute | 0.612675 |
| IRMN).Ampliar Imágenes | 0.62564 |
| siguientes tratamientos | 0.624353 |
| menor producción | 0.628805 |
| Instituto Nacional | 0.623964 |
| PDQ Tratamiento | 0.634123 |
| determinados cambios | 0.611022 |
| alta potencia | 0.625499 |
| presente sección | 0.614217 |
| nuevos tipos | 0.61878 |
| sistema nervioso central | 0.655496 |
| Physician Data Query | 0.650241 |
| siguientes pruebas | 0.680017 |
| siguientes estadios | 0.629707 |
| siguientes trastornos | 0.624626 |
|
CLICK HERE |
| 2023 |
National Cancer Institute |
Html |
es |
Prevención del cáncer de seno (mama) (PDQ®)–Versión para pacientes |
Sumario de información revisada por expertos sobre factores que influyen en el riesgo de presentar cáncer de mama y sobre las investigaciones dirigidas a la prevención de esta enfermedad. |
| Risk Assessment Tool | 0.639814 |
| enfermedad benigna | 0.724402 |
| voluntarios sanos | 0.550874 |
| siguientes afecciones | 0.583572 |
| posibles daños | 0.559702 |
| vÃa oral | 0.551992 |
| largo plazo | 0.555083 |
| carcinoma lobulillar situ | 0.643038 |
| National Cancer Institute | 0.566999 |
| vitamina a | 0.552574 |
| siguientes riesgos | 0.550628 |
| Instituto Nacional | 0.618668 |
| protección ayuda | 0.699167 |
|
| Physician Data Query | 0.746401 |
| Estados Unidos | 0.579171 |
| suficiente ejercicio | 0.906195 |
| siguientes caracterÃsticas | 0.59401 |
| prevención revisa | 0.554009 |
| PDQ Prevención | 0.599371 |
| Menor exposición | 0.569365 |
| siguientes formas | 0.705774 |
| pequeñas llamadas lobulillos | 0.645602 |
| Mayor edad | 0.567138 |
| genes brca1 | 0.883252 |
| conductos.ampliar anatomÃa | 0.589939 |
| siguientes sumarios | 0.661886 |
|
CLICK HERE |
| 2064 |
National Cancer Institute |
Html |
es |
Exposición al asbesto y el riesgo de cáncer |
Hoja informativa sobre el asbesto, sobre las enfermedades relacionadas con el asbesto e incluye organizaciones para obtener más información. |
| técnicos profesionales automotrices | 0.5421 |
| gen bap1 | 0.530949 |
| que familiares de trabajadores | 0.533144 |
| normas descritas | 0.532666 |
| largo plazo | 0.526581 |
| Protección Ambiental | 0.672505 |
| World Trade Center | 0.546459 |
| principal dependencia | 0.532045 |
| Ground Zero | 0.529197 |
| derrames pleurales benignos | 0.558277 |
| Salud Ocupacional | 0.584399 |
| asbesto crisótilo | 0.987156 |
| trabajadores portuarios | 0.606054 |
| Instituto Nacional | 0.563708 |
| menores riesgos | 0.533274 |
| Trabajo de EE | 0.535904 |
| Employment Standards Administration | 0.548898 |
| titulado current best practices | 0.543841 |
| Mine Safety | 0.535362 |
| sustancias tóxicas | 0.635631 |
| siglo xix | 0.53032 |
| distintos tipos | 0.525229 |
| Estados Unidos | 0.992615 |
| automotriz usa | 0.531695 |
| Public Affairs | 0.529764 |
|
| serios problemas | 0.529441 |
| Environmental Protection Agency | 0.815767 |
| lÃnea telefónica tsca | 0.556811 |
| Preventing Asbestos Exposure | 0.544747 |
| Product Safety Commission | 0.67091 |
| Information Division | 0.52746 |
| Occupational Safety | 0.586355 |
| asbesto causa | 0.952053 |
| cuánto tiempo | 0.527545 |
| en la mucosidad | 0.531534 |
| a las personas | 0.529484 |
| posibles peligros | 0.5266 |
| Health Administration | 0.652906 |
| Consumer Product Safety | 0.672282 |
| causa dificultad | 0.530297 |
| sumamente bajo. Los fabricantes | 0.528798 |
| mejores prácticas | 0.574094 |
| Clutch Repair Workers | 0.544379 |
| Veterans Affairs | 0.528386 |
| Torres Gemelas | 0.52642 |
| Compensation Programs | 0.5287 |
| Disease Registry | 0.526245 |
| Toxic Substances | 0.526971 |
| Segunda Guerra Mundial | 0.550565 |
|
CLICK HERE |
| 3424 |
National Cancer Institute |
Html |
es |
Informes de patología |
Hoja informativa que describe el tipo de información que puede aparecer en un informe de patología, el cual contiene los resultados de la examinación visual y microscópica del tejido extirpado durante una biopsia o cirugía. |
| página del nci | 0.749066 |
| cromosoma filadelfia | 0.760969 |
| ¿Cuánto tiempo | 0.803391 |
| leucemia mielógena | 0.766464 |
| tipo southern | 0.748591 |
|
| Detecta fragmentos | 0.751768 |
| simple vista | 0.960274 |
| Instituto Nacional | 0.833257 |
| cuello uterino | 0.83163 |
|
CLICK HERE |
| 16822 |
National Cancer Institute |
Html |
es |
Essiac y Flor Essence (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de Essiac o Flor Essence como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| Centro Nacional | 0.301601 |
| New Hampshire Avenue | 0.301144 |
| Drug Administration | 0.30071 |
| Flor Essence | 0.987323 |
| NCI Best Case | 0.302063 |
| modelos animales | 0.300855 |
| Indiana University-Purdue University | 0.301652 |
| datos bibliográficos pubmed | 0.301216 |
| siguientes preguntas | 0.300694 |
| productos essiac | 0.309556 |
| modelo animal | 0.300781 |
| PDQ Essiac | 0.318217 |
| National Cancer Institute | 0.301364 |
| Royal Cancer Commission | 0.301752 |
| Olmo resbaladizo | 0.301149 |
| siguientes riesgos | 0.300858 |
| Instituto Nacional | 0.309533 |
| Salud Complementaria | 0.302607 |
|
| Visuals Online | 0.300813 |
| complementarias revisa | 0.30115 |
| Physician Data Query | 0.304689 |
| Sloan Kettering Cancer | 0.301678 |
| Estados Unidos | 0.332086 |
| siguientes estudios | 0.301314 |
| libre uso | 0.301062 |
| distintos resultados | 0.300776 |
| únicos efectos | 0.301309 |
| ratón p388 | 0.301025 |
| página manejo | 0.300756 |
| ¿El tratamiento | 0.301379 |
| Nueva York | 0.300871 |
| ¿Los beneficios | 0.30071 |
| juntos cam | 0.300681 |
| Series Program | 0.300695 |
| medicina complementaria | 0.332457 |
|
CLICK HERE |
| 17171 |
National Cancer Institute |
Html |
es |
PC-SPES (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre el uso de PC-SPES como tratamiento del cáncer de próstata. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta. |
| médico herborista | 0.418438 |
| Centro Nacional | 0.430037 |
| New Hampshire Avenue | 0.420405 |
| Drug Administration | 0.412734 |
| NCI Best Case | 0.437012 |
| datos bibliográficos pubmed | 0.422243 |
| siguientes preguntas | 0.413766 |
| demostró efectos | 0.424258 |
| siguientes riesgos | 0.417668 |
| seguro médico | 0.412292 |
| múltiples problemas | 0.418438 |
| Instituto Nacional | 0.517971 |
| acupuntura ayuda | 0.412243 |
| Salud Complementaria | 0.450225 |
| Visuals Online | 0.415643 |
|
| complementarias revisa | 0.422417 |
| Physician Data Query | 0.491682 |
| Estados Unidos | 0.863449 |
| actúa pc-spes | 0.442835 |
| libre uso | 0.415953 |
| suficiente cantidad | 0.41905 |
| página manejo | 0.414584 |
| ¿El tratamiento | 0.421322 |
| Nueva York | 0.418373 |
| ¿Los beneficios | 0.413162 |
| siguientes medicamentos | 0.438285 |
| Series Program | 0.413051 |
| medicina complementaria | 0.925538 |
| diferentes lotes | 0.423892 |
|
CLICK HERE |